News Releases
Jun 23 2003
Peregrine's Vasopermeation Enhancement Agent Technology Highlighted In Nature Reviews Cancer
Jun 20 2003
Peregrine's Phosphatidylserine Based Vascular Targeting Agent Technology Presented at the Angiogenesis II Conference in Paris, France
Jun 18 2003
Peregrine and Affitech to Collaborate on Developing Fully Human Vascular Targeting Agent Antibodies
Jun 12 2003
Peregrine Regains Compliance with Nasdaq Listing Requirements
Jun 9 2003
Peregrine Pharmaceuticals Raises Over $2 Million From Institutional Investors; $1.5 Million In Debt Converted
Jun 4 2003
Peregrine's Vascular Targeting Agent Effective In Combination Cancer Therapy
May 21 2003
Peregrine's Vasopermeation Enhancement Agent Technology Published In Journal Of The National Cancer Institute
May 20 2003
Peregrine Clarifies Its Anti-Angiogenesis VEGF Antibody and Vascular Targeting Agents Compared to Other VEGF Antibodies
Apr 2 2003
Avid Bioservices Signs Manufacturing Supply Agreement For The Production Of Four Monoclonal Antibodies
Mar 25 2003
Peregrine Pharmaceuticals Announces Grant of Patent For Vasopermeation Enhancing Agents